Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 17-Jan-24 5:19 PM View:  | Lowinger Timothy B SVP, Chief Sci.&Tech. Officer | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 10,409 | $2.71 | $28,208.40 | (5%) 209.74K to 199.33K | |
| 17-Jan-24 5:20 PM View: | Mandelia Ashish VP, Chief Accounting Officer | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 5,025 | $2.71 | $13,617.80 | (18%) 28.35K to 23.33K | |
| 17-Jan-24 5:21 PM View: | Protopapas Anna Director | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 29,399 | $2.71 | $79,671.30 | (6%) 467.06K to 437.66K | |
| 17-Jan-24 5:16 PM View: | Bala Mohan SVP, Chief Development Officer | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 3,431 | $2.71 | $9,298.01 | (20%) 17.48K to 14.05K | |
| 17-Jan-24 5:18 PM View: | Deschuytner Brian SVP, COO & CFO | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 9,327 | $2.71 | $25,276.20 | (15%) 63.84K to 54.51K | |
| 17-Jan-24 5:18 PM View: | Carvajal Alejandra SVP, Chief Legal Officer | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 4,381 | $2.71 | $11,872.50 | (14%) 31.78K to 27.4K | |
| 17-Jan-24 5:21 PM View: | Misra Tushar SVP, Chief Manuf. Officer | Mersana Therapeutics, Inc. (MRSN) | 16-Jan-24 | Planned Option Sale | 3,357 | $2.71 | $9,097.47 | (16%) 21.32K to 17.97K | |
| 17-Jan-24 5:21 PM View: | Protopapas Anna Director | Mersana Therapeutics, Inc. (MRSN) | 15-Jan-24 | Option Exercise | 38,958 | -- | -- | 9% 428.1K to 467.06K | |
| 17-Jan-24 5:18 PM View: | Deschuytner Brian SVP, COO & CFO | Mersana Therapeutics, Inc. (MRSN) | 15-Jan-24 | Option Exercise | 10,208 | -- | -- | 19% 53.63K to 63.84K | |
| 17-Jan-24 5:19 PM View: | Lowinger Timothy B SVP, Chief Sci.&Tech. Officer | Mersana Therapeutics, Inc. (MRSN) | 15-Jan-24 | Option Exercise | 15,208 | -- | -- | 8% 194.53K to 209.74K | |
| 17-Jan-24 5:20 PM View: | Mandelia Ashish VP, Chief Accounting Officer | Mersana Therapeutics, Inc. (MRSN) | 15-Jan-24 | Option Exercise | 5,352 | -- | -- | 23% 23.0K to 28.35K | |
| 17-Jan-24 5:18 PM View: | Deschuytner Brian SVP, COO & CFO | Mersana Therapeutics, Inc. (MRSN) | 14-Jan-24 | Option Exercise | 6,250 | -- | -- | 13% 49.38K to 55.63K | |
| 17-Jan-24 5:18 PM View: | Carvajal Alejandra SVP, Chief Legal Officer | Mersana Therapeutics, Inc. (MRSN) | 14-Jan-24 | Option Exercise | 2,500 | -- | -- | 9% 29.28K to 31.78K | |
| 17-Jan-24 5:19 PM View: | Lowinger Timothy B SVP, Chief Sci.&Tech. Officer | Mersana Therapeutics, Inc. (MRSN) | 14-Jan-24 | Option Exercise | 4,792 | -- | -- | 3% 189.74K to 194.53K | |
| 17-Jan-24 5:21 PM View: | Misra Tushar SVP, Chief Manuf. Officer | Mersana Therapeutics, Inc. (MRSN) | 14-Jan-24 | Option Exercise | 1,458 | -- | -- | 7% 19.86K to 21.32K | |
| 17-Jan-24 5:20 PM View: | Mandelia Ashish VP, Chief Accounting Officer | Mersana Therapeutics, Inc. (MRSN) | 14-Jan-24 | Option Exercise | 4,783 | -- | -- | 26% 18.22K to 23.0K | |
| 17-Jan-24 5:21 PM View: | Protopapas Anna Director | Mersana Therapeutics, Inc. (MRSN) | 14-Jan-24 | Option Exercise | 16,750 | -- | -- | 4% 411.35K to 428.1K | |
| 17-Jan-24 5:18 PM View: | Carvajal Alejandra SVP, Chief Legal Officer | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 8,958 | -- | -- | 44% 20.33K to 29.28K | |
| 17-Jan-24 5:19 PM View: | Lowinger Timothy B SVP, Chief Sci.&Tech. Officer | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 9,375 | -- | -- | 5% 180.36K to 189.74K | |
| 17-Jan-24 5:21 PM View: | Misra Tushar SVP, Chief Manuf. Officer | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 7,083 | -- | -- | 55% 12.78K to 19.86K | |
| 17-Jan-24 5:20 PM View: | Mandelia Ashish VP, Chief Accounting Officer | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 2,645 | -- | -- | 17% 15.57K to 18.22K | |
| 17-Jan-24 5:16 PM View: | Bala Mohan SVP, Chief Development Officer | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 8,750 | -- | -- | 100% 8.73K to 17.48K | |
| 17-Jan-24 5:21 PM View: | Protopapas Anna Director | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 31,250 | -- | -- | 8% 380.1K to 411.35K | |
| 17-Jan-24 5:18 PM View: | Deschuytner Brian SVP, COO & CFO | Mersana Therapeutics, Inc. (MRSN) | 13-Jan-24 | Option Exercise | 10,000 | -- | -- | 27% 37.38K to 47.38K | |
| 04-Jan-24 4:11 PM View: | Dere Willard H Director | Mersana Therapeutics, Inc. (MRSN) | 02-Jan-24 | Grant | 6,112 | -- | -- | 18% 33.07K to 39.18K | |
| 04-Jan-24 4:11 PM View: | Mott David M Director | Mersana Therapeutics, Inc. (MRSN) | 02-Jan-24 | Grant | 8,810 | -- | -- | 1% 589.48K to 598.29K | |
| 27-Oct-23 4:07 PM View: | Bala Mohan SVP, Chief Development Officer | Mersana Therapeutics, Inc. (MRSN) | 26-Oct-23 | Planned Option Sale | 1,912 | $1.13 | $2,160.56 | (18%) 10.64K to 8.73K | |
| 27-Oct-23 4:07 PM View: | Bala Mohan SVP, Chief Development Officer | Mersana Therapeutics, Inc. (MRSN) | 25-Oct-23 | Option Exercise | 6,250 | -- | -- | 142% 4.39K to 10.64K | |
| 04-Oct-23 4:26 PM View: | Mott David M Director | Mersana Therapeutics, Inc. (MRSN) | 02-Oct-23 | Grant | 15,873 | -- | -- | 3% 573.61K to 589.48K | |
| 04-Oct-23 4:30 PM View: | Dere Willard H Director | Mersana Therapeutics, Inc. (MRSN) | 02-Oct-23 | Grant | 11,011 | -- | -- | 50% 22.06K to 33.07K | |
| 13-Sep-23 4:02 PM View: | Protopapas Anna Director | Mersana Therapeutics, Inc. (MRSN) | 11-Sep-23 | Grant | 16,643 | -- | -- | 5% 363.46K to 380.1K | |
| 18-Aug-23 4:01 PM View: | Misra Tushar SVP, Chief Manuf. Officer | Mersana Therapeutics, Inc. (MRSN) | 17-Aug-23 | Planned Option Sale | 1,908 | $1.18 | $2,251.44 | (14%) 13.41K to 11.51K | |
| 18-Aug-23 4:01 PM View: | Misra Tushar SVP, Chief Manuf. Officer | Mersana Therapeutics, Inc. (MRSN) | 16-Aug-23 | Option Exercise | 6,250 | -- | -- | 87% 7.17K to 13.41K | |
| 06-Jul-23 4:19 PM View: | Dere Willard H Director | Mersana Therapeutics, Inc. (MRSN) | 03-Jul-23 | Grant | 4,217 | -- | -- | 24% 17.84K to 22.06K | |
| 06-Jul-23 4:18 PM View: | Mott David M Director | Mersana Therapeutics, Inc. (MRSN) | 03-Jul-23 | Grant | 6,079 | -- | -- | 1% 567.53K to 573.61K | |
| 12-Jun-23 4:13 PM View: | Dere Willard H Director | Mersana Therapeutics, Inc. (MRSN) | 08-Jun-23 | Grant | 14,467 | -- | -- | 429% 3.38K to 17.84K | |
| 12-Jun-23 5:25 PM View: | Hack Andrew A. F. Director | Mersana Therapeutics, Inc. (MRSN) | 08-Jun-23 | Grant | 14,467 | -- | -- | < 1% 8.66M to 8.68M | |
| 12-Jun-23 10:00 PM View: | Mott David M Director | Mersana Therapeutics, Inc. (MRSN) | 08-Jun-23 | Grant | 14,467 | -- | -- | 3% 553.06K to 567.53K | |
| 12-Jun-23 4:19 PM View: | Diaz Allene M. Director | Mersana Therapeutics, Inc. (MRSN) | 08-Jun-23 | Grant | 14,467 | -- | -- | 100% 0 to 14.47K | |
| 12-Jun-23 4:17 PM View: | Hege Kristen Director | Mersana Therapeutics, Inc. (MRSN) | 08-Jun-23 | Grant | 14,467 | -- | -- | 100% 0 to 14.47K | |
| 12-Jun-23 4:14 PM View: | Alleva Lawrence M Director | Mersana Therapeutics, Inc. (MRSN) | 08-Jun-23 | Grant | 14,467 | -- | -- | 682% 2.12K to 16.59K | |
| 12-Jun-23 4:16 PM View: | Huber Martin H. Jr. Director | Mersana Therapeutics, Inc. (MRSN) | 08-Jun-23 | Grant | 14,467 | -- | -- | 100% 0 to 14.47K | |
| 28-Apr-23 4:15 PM View: | Carvajal Alejandra SVP, Chief Legal Officer | Mersana Therapeutics, Inc. (MRSN) | 27-Apr-23 | Planned Option Sale | 3,944 | $3.89 | $15,342.20 | (16%) 24.27K to 20.33K | |
| 28-Apr-23 4:15 PM View: | Carvajal Alejandra SVP, Chief Legal Officer | Mersana Therapeutics, Inc. (MRSN) | 26-Apr-23 | Option Exercise | 13,250 | -- | -- | 120% 11.02K to 24.27K | |
| 05-Apr-23 5:14 PM View: | Mott David M Director | Mersana Therapeutics, Inc. (MRSN) | 03-Apr-23 | Grant | 4,866 | -- | -- | < 1% 548.19K to 553.06K | |
| 05-Apr-23 5:12 PM View: | Dere Willard H Director | Mersana Therapeutics, Inc. (MRSN) | 03-Apr-23 | Grant | 3,375 | -- | -- | 100% 0 to 3.38K | |
| 18-Jan-23 8:09 PM View: | Carvajal Alejandra SVP, Chief Legal Officer | Mersana Therapeutics, Inc. (MRSN) | 17-Jan-23 | Option Sale | 782 | $5.74 | $4,488.68 | (7%) 11.8K to 11.02K | |
| 18-Jan-23 8:29 PM View: | Yang Arvin SVP, Chief Medical Officer | Mersana Therapeutics, Inc. (MRSN) | 17-Jan-23 | Option Sale | 2,209 | $5.74 | $12,679.70 | (7%) 33.03K to 30.82K | |
| 18-Jan-23 8:24 PM View: | Protopapas Anna President & CEO Director | Mersana Therapeutics, Inc. (MRSN) | 17-Jan-23 | Option Sale | 17,346 | $5.74 | $99,566.00 | (5%) 378.59K to 361.24K | |
| 18-Jan-23 8:14 PM View: | Lowinger Timothy B SVP, Chief Sci.&Tech. Off. | Mersana Therapeutics, Inc. (MRSN) | 17-Jan-23 | Option Sale | 6,233 | $5.74 | $35,777.40 | (3%) 186.6K to 180.36K |
